C-RAD AB and ScandiDos AB are joining sales forces in the USA
Press release 2013-0624
ScandiDos AB and C-RAD AB are two Swedish companies working in radiation therapy. Both companies are developing and marketing innovative solutions to improve quality and precision when treating patients with cancer.
The companies have decided to merge resources on the important US market with the objective to offer a complete program for high quality control to the clinics. C-RAD is in the US marketing and selling two different systems for use in advanced radiation therapy:
The Catalyst system is based on a new generation hardware and software platform for high performance optical surface scanning and augmented reality through re-projection. Advanced and highly optimized algorithms for non-rigid registration and deformable models enable real-time assessment of patient positioning errors before and during treatment delivery. The C-RAD Sentinel system, based on laser technology, is offering advanced functionality for 4DCT. ScandiDos is in the US marketing and selling the product family Delta4 to quality control advanced radiation therapy, from treatment plan to the last delivered treatment fraction. ScandiDos introduced a paradigm shift in Radiation Therapy QA with real 3D and 4D dosimetry and thereby uniquely combine high quality measurements with time efficiency and clinical relevance. Recently ScandiDos released the product HexaMotion for quality control in next generation radiation therapy, 4DRT and Delta4DVH Anatomy to visualize measured dose in patient anatomy. ScandiDos will soon release Delta4AT that uniquely address the patient dosimetry demand.
C-RAD Inc. and ScandDos Inc. have set up an organization for USA and Canada with five regions. The group will be responsible for sales to more than 3000 clinics. The regions will be supported by application specialists, a service group and a function for in-house sales. The combined group will be managed and coordinated by Mr. Lars Jordeby. Mr. Jordeby has a long experience in marketing and sales of both C-RAD and ScandiDos systems.
Erik Hedlund, CEO, C-RAD AB:
“We are looking forward to work with ScandiDos on the North American market. By joining forces we will be able to offer high precision solutions for quality assurance of the linacs and set up and monitoring of patients. The new organization will offer complete and professional support to all customers in USA and Canada.”
Görgen Nilsson, CEO, ScandiDos AB:
“ScandiDos and C-RAD have great similarities being ground breaker in separate radiation therapy niches. The collaboration is thereby natural and we look forward to it and to the intensein sales activities this will create in North America”
About ScandiDos
ScandiDos has in the last five years become the worldwide leader in validating advanced radiation therapy utilizing Delta4 and thereby ensure correct treatment delivery in e.g. IMRT and VMAT. The Delta 4 family is a platform with advanced devices to measure the treatment dose prior and during the patient treatment, analysis the dose data in a fast and accurate way and also find causes to any discrepancy when comparing planed and delivered treatment dose.
ScandiDos is currently a privately owned company with 27 employee based in the main office in Uppsala Sweden,
ScandiDos Inc in US and ScandiDos Beijing in China. The company is specialist in product development, sales and support; and collaborates with major vendors in radiation therapy. The products are widely spread over all continents.
For more information, please visit:
www.scandidos.com
About C-RAD
C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems.
End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-
RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 24eople. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the CRAD SentinelTM,started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RADWOFE in China. C-RAD has acquired 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %.
C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.
For more information on C-RAD, please visit www.c-rad.com
For further information:
Erik Hedlund, CEO C-RAD AB, Phone +46-18-66691,
E-mail erik.hedlund@c-rad.se
Görgen Nilsson, CEO ScandiDos AB,
Phone +46 18472 3032, e-mail gorgen.nilsson@scandidos.com